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Abstract: Prognosis of patients with carcinoma of the exocrine pancreas is particularly 
poor. A combination of chemotherapy with immunotherapy could be an option for 
treatment of pancreatic cancer. The aim of this study was to perform an immunomonitoring 
of 17 patients with pancreatic cancer from the CapRI-2 study, and tumor-bearing mice 
treated with combination of chemo (radio) therapies with interferon-2α. Low doses of 
interferon-2α led to a decrease in total leukocyte and an increase in monocyte counts. 
Furthermore, we observed a positive effect of interferon-2α therapy on the dendritic cells 
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and NK (natural killer) cell activation immediately after the first injection. In addition, we 
recorded an increased amount of interferon-γ and IL-10 in the serum following the 
interferon-2α therapy. These data clearly demonstrate that pancreatic carcinoma patients 
also show an immunomodulatory response to interferon-2α therapy. Analysis of 
immunosuppressive cells in the Panc02 orthotopic mouse model of pancreatic cancer 
revealed an accumulation of the myeloid-derived suppressor cells in spleens and tumors of 
the mice treated with interferon-2α and 5-fluorouracil. The direct effect of the drugs on 
myeloid-derived suppressor cells was also registered in vitro. These data expose the 
importance of immunosuppressive mechanisms induced by combined chemo-immunotherapy.  
Keywords: immunomonitoring; immunotherapy; interferon-α; CapRI; pancreatic carcinoma; 
Panc02 orthotopic model  
 
1. Introduction 
Patients with pancreatic ductal adenocarcinoma are characterized by an especially poor prognosis 
reaching a five-year survival rate only in about 1% of cases and a median survival of four to six 
months. After resection, the five-year survival rate is at best 15% to 25% with additional adjuvant 
chemotherapy [1]. This cancer type represents globally one of the most aggressive malignancies. 
Adjuvant chemotherapy based on gemcitabine or 5-fluorouracil (5-FU) shows an increase in overall 
and disease-free survival [2–4]. However, the clinical impact of these chemotherapeutics remains 
modest. Therefore, new treatment options are urgently needed to improve the survival of patients with 
pancreatic cancer. Immunotherapy could be an attractive approach for treating such patients. 
It has become increasingly clear that immunotherapy provides a promising option for cancer 
treatment [5], especially following the encouraging results from the Ipilimumab clinical study in 
malignant melanoma [6]. Furthermore, a combination of chemotherapy with immunotherapy can offer 
synergies and deliver improved efficiency in pancreatic cancer compared to current therapies [7]. As a 
result, combining standard chemotherapy with immunotherapy can provide a unique treatment of 
pancreatic cancer.  
The first clinical phase III trial, dealing with the combination of 5-FU and interferon-2α (IFN), was 
the CapRI study [8]. IFN belongs to the group of type I interferons, which are already used in cancer 
therapy (e.g., malignant melanoma (metastatic [9] and adjuvant [10,11]), renal cell carcinoma (RCC) [12], 
and some other malignancies). IFN exhibits several features that might be of interest, especially for use 
in combination treatments of cancer, as there are: (i) direct inhibitory effects on tumor cell growth [13–17]; 
(ii) radio- and chemo-sensitizing effects [14,15,18]; (iii) anti-angiogenic properties [14,19];  
(iv) enhancement of tumor immunogenicity (increase of MHC class I expression [20]); (v) modulation 
of the immune system: improving differentiation, maturation and function of dendritic cells (DC), 
enhancing the survival of T cells by expression of anti-apoptotic genes, generation of CD8+ memory 
cells, enhancing macrophage activities, and activating natural killer (NK) cells [20]. 
Clinical data from the CapRI study did not point at improved efficiency of the combination regime 
when compared to chemo-radiotherapy alone [21]. Despite this, the clinical outcome in both groups 
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represent the best ever reported survival for patients with resected pancreatic cancer in randomized 
trials. In view of these findings, and the fact that the CapRI study revealed considerable toxicity of  
the combination treatment, a pilot trial (CapRI-2) was initiated to evaluate the influence of de-escalation 
of the CapRI regime on the immunological parameters by the omission of cisplatin and/or beam  
radiation [22]. 
The main aim of this research was the investigation of immunological effects of the type I 
interferon IFN and chemo-radio-immunotherapy with IFN and 5-FU in patients from the CapRI-2 trial, 
and in mice from the Panc02 orthotopic pancreatic carcinoma model.  
2. Results 
2.1. Human Study: Clinical Data 
For the CapRI-2 study, 17 patients were recruited. All relevant clinical characteristics are 
summarized in Table 1. It should be pointed out that, during the study, the R1 resection had been 
redefined [23], thus, the majority of patients were adjusted from R0 to R1. The patients’ data, such as 
gender, resection type, tumor grade, TNM classification, and relapse did not show any significant 
differences between the several study arms (Table S1). Remarkably, six out of 17 patients were still 
alive and in good health with a maximal overall survival (OS) of 63 months (Table 1). The low number 
of patients in each study group unfortunately did not allow for a correct statistical analysis. 
Nonetheless, at least a certain number of two-year and five-year survivors could be calculated for each 
arm (Table S1). While no patient out of group A and C reached the five-year surviving edge, two 
patients out of group B (33%) successfully survived the five-year edge (Table S1). 
Table 1. Patients’ characteristics. 
Arm/ 
Treatment 





Relapse/Location DFS *, 
Month 







A1 M 52 R1 G2 pT3, pN1 (7/32), pMx Liver 15 Dead 16 
A2 F 47 R1 G2 pT3, pN1 (2/24), pMx 0 20 Alive 20 
A3 M 58 R1 G2 pT3, pN1(8/49), pMx Liver 4 Dead 12 
A4 M 50 R1 G2 pT2, pN1(1/6), M0 Peritonealcarcinosis 18 Dead 23 





B1 M 64 R1 G2 pT3, pN1 (6/22), pMx Liver 3 Alive 63 
B2 F 69 R0 G2 pT3, pN1 (1/37), pMx 0 63 Alive 63 
B3 F 60 R1 G2 pT3, pN1 (3/28), pMx Liver 15 Dead 21 
B4 M 65 R0 n.d. *** pT3 pN1 (1/17), cM0 0 53 Alive 53 
B5 M 54 R1 G2 pT3 pN1 (18/58), cM0 Peritonealcarcinosis 17 Dead 48 




C1 F 67 R1 G2 pT3, pN1(3/24), M0 Liver 27 Dead 48 
C2 M 63 R1 G2 pT3, pN1 (10/29), Mx 0 47 Alive 47 
C3 M 59 R1 G2 pT3, pN1 (5/29), pMx Liver 12 Dead 20 
C4 F 69 R1 G2 pT3, pN1(5/21), pMx Liver 3 Dead 7 
C5 M 62 R1 G2 pT3 pN1 (13/27), M0 Liver 19 Dead 38 
C6 F 65 R1 G3 pT3, pN0 (0/43), M0 Peritonealcarcinosis 4 Dead 7 
* DFS—disease free survival; ** OS—overall survival; *** n.d.—no data. 
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2.2. Human Study: Immunological Effects of IFN Only 
The initial phase of treatment was the same for groups A, B, and C (see Figure 1), which was why 
the impact of the first dose of IFN on immunological parameters could be evaluated for all 17 patients 
together. Treatment with the first low-dose of IFN led to a significant decrease in absolute amount of 
leukocytes (Figure 2a). From total leukocyte, the percentage of monocytes showed a high tendency to 
be increased (p = 0.077) (Figure 2b). Our FACS analysis also showed an increase in the cells within 
the monocyte gate (CD45+CD33+CD14+) immediately following a low-dose of IFN (Figures 2c and S1). 
Next, cells were additionally gated for dendritic cells (CD45+CD33+CD11c+CD14−) and investigated 
for the expression of HLA (human leukocyte antigen)-DR, CD80, and CD86 surface markers. We 
recorded an increase in DC following the first low-dose of IFN (Figures 2d and S1). For CD86  
and HLA-DR, we also found a rise in their expression immediately after a low-dose of IFN  
(Figures 2e,f, and S2). A change in the CD80 expression was not obvious (data not shown).  
Figure 1. CapRI-2 therapy schema and time-points of blood withdrawal during the 
therapy. Blood samples were taken from the patients immediately before the first IFN 
injection (pre low-dose IFN (preLDI)), one day after (onLDI), immediately before the start 
of the first cycle of chemo-radio-immunotherapy or chemotherapy (pre1), one day after 
(on1), before the start of the second cycle of chemo-radio-immunotherapy or chemotherapy 
(pre2) and after a third cycle of the therapy (end). EBR—external beam radiation,  
Cis—cisplatin. 
 
We also examined whether preLD1 and pre1 points could differ in their lymphocyte count. We did 
not observe any differences between preLD1 and pre1 in this respect (data not shown). Afterwards 
CD8+, CD4+ and regulatory T cells (Treg, CD3+CD4+CD25highFoxP3+) in the lymphocyte gate were 
analyzed for their amounts and their phenotype and/or their activation status. We did not observe 
significant changes in relative numbers of T cell subsets (data not shown) in this instance. In addition, 
no differences were found in their activation status (based on the CD69 expression) after the first  
low-dose of IFN (data not shown). In a functional test, we did not observe an increase in granzyme B 
release during the course of IFN therapy after stimulation of patients’ PBMC (Peripheral blood 
mononuclear cells) with a CA19.9 peptide or with a MUC-1 peptide (data not shown). 
In the current study, we also investigated an expression of the cytotoxic T-lymphocyte antigen 4 
(CTLA4) on the surface of all CD4+ T cells following the first dose of IFN. We found no difference 
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between the preLDI and onLDI in this instance: some patients responded to the low dose of IFN with 
an increase in CTLA4, some with a decrease and others showed no change (Figure S3). Additionally, 
we measured Treg in the CD4+ lymphocyte compartment; however, we did not observe any differences 
in their amount or in the CTLA4 or FoxP3 expression in these cells (data not shown). 
Figure 2. Analysis of leukocytes, monocytes and dendritic cells (DC) in peripheral blood 
of patients from the CapRI-2 study. (a) Absolute amount of leukocytes and (b) relative 
amount of monocytes during the course of IFN therapy (clinical chemistry), no data for 
onLDI; (c) the relative amount of monocytes in total leukocytes during the course of IFN 
therapy in all patients and in all therapeutic groups; (d) DC and their co-stimulatory 
markers during the course of IFN therapy (e) and (f). The immunological parameters of  
17 patients were analyzed, * p < 0.05. 
 
Furthermore, we were interested in analyzing NK cells in the CapRI-2 patients. Whilst the total 
number of NK cells did not change, our FACS analysis revealed a significant increase in the activation 
status of NK cells, either in total NK cell population (CD45+CD56+) or in NKCD8− or NKCD8+ cells 
(Figures 3 and S4). It should be noted that such activation dropped out to the time point pre1. An 
enhancement of activation indicated by upregulation of NKG2D receptors was detected immediately 
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after a low-dose of IFN (Figures 3 and S4). Using chromium release assay against K562 cells, we 
investigated NK cell-mediated cytotoxicity. We could not demonstrate significant changes in 
cytotoxicity after the first low dose of IFN (data not shown). 
Figure 3. FACS analysis of NK cells and their activation state in the peripheral blood of 
patients. NK cells: expression of NKG2D on the surface of all CD45+CD56+ cells (a); 
CD45+CD56+CD8− cells (b) and CD45+CD56+CD8+ cells (c) during the course of IFN 
therapy. The immunological parameters of 17 patients were analyzed, * p < 0.05. 
 
2.3. Human Study: Effects of Chemo-Radio-Immunotherapy on Immunological Parameters 
During the course of chemo-radio-immunotherapy, we observed a decreasing trend in the absolute 
amount of leukocytes (Figure S5a) and an increase in the monocyte subpopulation (Figure S5b) 
independent from the applied therapy. In addition, we detected a decrease in lymphocyte count during 
the chemotherapy/chemo-radiotherapy (ON1 vs. pre2) (Figure S5c). No difference was detected in the 
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DC and in the expression of CD86, CD80, and HLA-DR on the surface of DC between the groups  
(data not shown). Furthermore, no difference was observed both in the relative numbers of T cell 
subsets or in the granzyme B release between the groups (data not shown). Following the second IFN 
injection, there was also no change detected in the total number of NK cells. However, we recorded an 
increasing trend in the NK cell activation independent from the applied therapy (Figure S6). There 
were no significant differences in the NK cytotoxicity, either during the course of IFN treatment or 
between the groups (data not shown).  
Figure 4. Cytokine level in the serum of patients before and after low-dose of IFN. The 
serum of 17 patients was analyzed, * p < 0.05. 
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2.4. Human Study: Effects of Chemo-Radio-Immunotherapy on Serum Cytokines 
Patients’ serum samples were taken at the following time-points: preLDI, pre1, on1, pre2, and end, 
for analysis of IFNγ, TNFα, IP10, IL12, IL17, and IL10 cytokines. We found an elevated level of IFNγ 
and IL-10 in the patients’ serum immediately following low-doses of IFN (Figure 4). High heterogeneity 
of patients in respect to initial serum level was observed for some cytokines (data not shown). We did 
not observe any difference in cytokine levels between the groups (data not shown).  
2.5. Mouse Study: In Vivo Effects of Chemo-Immunotherapy on Immunological Parameters 
To extend our human in vivo data, we performed an immunomonitoring of tumor-bearing mice  
with pancreatic carcinoma treated with a combination of IFN and 5-FU. As the combination of  
IFN with chemo-radiotherapy is extremely toxic to mice (data not shown), we used only  
chemo-immunotherapy for the mouse treatment. As expected, the combination of IFN with 5-FU 
reduced the tumor growth significantly (Figure S7). The subsequent FACS (fluorescence-activated cell 
sorting, flow cytometry) analysis of splenocyte and tumor cell suspensions revealed a decrease in the 
CD4+ lymphocyte accumulation in the spleen and tumor (Figure 5a). With regard to the expression of 
the earlier activation marker CD69, we found an increase in the percentage of CD69+CD4+ T cells in 
the spleen following the combined treatment, and a tendency to a reduction of the cell percentage in 
the tumor (Figure 5a). For the CD8+ lymphocytes, we did not detect any change in percentage of the 
cells in either the spleens or the tumors, but a decrease in percentage of the activated (CD69+) 
lymphocytes (Figure 5b). Additionally, while there was no difference in the percentage of DC in the 
spleens of the tumor-bearing mice, a decrease in the percentage of DC was obvious in the mouse 
tumors following the treatment (Figure 6). It should be emphasized that the percentage of conventional 
T cells (Tcon, CD4+FoxP3−) had been reduced in the spleen and increased in the tumor of the  
tumor-bearing mice with pancreatic carcinoma (Figure 6), indicating a possible migration of Tcon to 
the tumor site. 
Investigation of the immunosuppressive arm during the combined therapy revealed that IFN in 
combination with 5-FU increased an accumulation of myeloid-derived suppressor cells (MDSC) in 
both the spleens and in the tumors of the treated tumor-bearing mice. There was, however, no effect on 
the Treg (CD4+CD25+FoxP3+) percentage (Figure 6). It should be stressed that in the control 
(untreated) group of mice, we found a promising negative correlation of tumor growth with CD4+ 
lymphocyte accumulation and an upward trend for a positive correlation of tumor growth with MDCS 
accumulation (Table 2). This demonstrates that MDSC were able to diminish the accumulation of 
CD4+ cell in the tumors. However, in the IFN + 5-FU treated group of mice, we could not find such a 
correlation (Table 2).  
Int. J. Mol. Sci. 2014, 15 4112 
 
 
Figure 5. FACS analysis of lymphocytes in the spleen and tumors of Panc02-bearing mice 
treated with a combination of IFN and 5-FU (IFN + 5-FU), and of control-treated animals 
(co). (a) CD4+ T cells and their activation; (b) CD8+ T cells and their activation in the 
spleen and tumors of Panc02 tumor-bearing mice, respectively. Six to eight animals per group, 
* p < 0.05, ** p < 0.01 and *** p < 0.001. 
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Figure 6. FACS analysis of DC, Tcon, Treg, and MDSC in the spleen and tumors of 
Panc02-bearing mice treated with a combination of IFN and 5-FU (IFN + 5-FU) and of 
contro-treated animals (co). Six to eight animals per group, * p < 0.05, and ** p < 0.01. 
 
Table 2. Spearman correlation of values CD4+ cells and MDSC (myeloid-derived 
suppressor cells) against tumor growth. 
 
CD4+ Cells MDSC 
r p r p 
Tumor growth 
co −0.94 0.017 0.83 0.058 
IFN −0.7 0.233 0.54 0.297 
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Figure 7. In vitro effects of therapies with IFN or 5-FU treatment only or their 
combination on splenocytes from tumor-bearing mice: FACS analysis of (a) lymphocytes; 
(b) CD4+ and CD8+ lymphocytes; (c) CD8+ effector cells; (d) CD69 expression on the 
surface of Tcon and Treg. Results of four independent experiments are presented,  
* p < 0.05, ** p < 0.01 and *** p < 0.001, co—control treated mice. 
 
2.6. Mouse Study: In Vitro Effects of Chemo-Immunotherapy on Immunological Parameters 
Finally, we wanted to examine whether the IFN or 5-FU, or combined IFN + 5-FU therapy had a 
direct effect on immune cells. To do this, we isolated splenocytes from the tumor-bearing mice and 
cultivated these in vitro for 24 h with the drugs or with the compound combination. FACS analysis of 
the cultivated splenocytes revealed an increase in the percentage of lymphocytes in the leukocyte gate 
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after the IFN treatment alone and in combination with 5-FU, but not after 5-FU treatment only  
(Figure 7a). It is interesting to note that the combined treatment changed the CD4+/CD8+ ratio, 
decreasing the CD4+ cell percentage and increasing the CD8+ one (Figure 7b). Treatment of the cells 
with IFN alone led to an increase in the percentage of CD8+ effector cells (Figure 7c). No influence on 
lymphocyte subpopulations (i.e., naïve, effector, effector-memory or central memory cells) was 
detected (data not shown). In addition, no in vitro effects of the treatments were found on the 
percentage of Treg, conventional T cells and macrophages (data not shown). However, IFN-treatment 
decreased the earlier activation of Tcon and Treg based on expression of the CD69 surface marker 
(Figure 7d). 5-FU treatment alone did not change the immunological parameters assessed. While 
MDSC as a whole and granulocytic subpopulation of these cells did not show changes after the 
treatment (data not shown), the percentage of monocytic MDSC was increased following IFN + 5-FU 
treatment (Figure 8a). In respect of DC, we found an upregulation of CD80 and CD86 co-stimulatory 
molecules on the surface of cDC and an increase in expression of CD80 on pDC following different 
treatments (Figure 8b); the percentage of DCs was not affected (data not shown).  
Figure 8. In vitro effects of therapies with IFN or 5-FU only or their combination on 
splenocytes from tumor-bearing mice: FACS analysis of (a) monocytic MDSC and  
(b) cDC and pDC. Results of four independent experiments are present, * p < 0.05,  
** p < 0.01 and *** p < 0.001, co—control treated mice.  
 




The results of the CapRI-1 trial did not feature a survival benefit for patients with pancreatic cancer 
by adding interferon Type I (IFN) to the chemotherapy regimen. The small group of recruited patients 
in the CapRI-2 trial unfortunately does not permit a precise and statistically relevant investigation of 
survival data. However, the particularity, that five-year survivors were only found among patients of 
group B, should arouse scientific interest and encourage new study designs. The benefit of patients in 
this group could be traced back to either the omission of cisplatin, or the higher amount of patients 
with R0 resection. 
Both in patients and in mice we observed a decrease of total leukocyte count. This result was in 
accordance with the IFN effects found in both healthy subjects [24] or in patients treated with  
IFN [25,26]. This could indicate that the decrease in leukocyte count is a response to IFN. Despite total 
decrease in leukocyte count, we observed an increase in the monocyte count between preLD1 and 
pre1. This was additionally supported by the data from FACS analyses, which demonstrated a 
significant increase in monocytes already being between preLD1 and onLD1. In our case, this 
upregulation was significant amongst all 17 patients following the first IFN doses (without an 
additional therapy); the same tendency after second IFN injection was observed between all three 
groups. Therefore, we speculate that IFN was primarily responsible for this effect without an 
additional impute of cisplatin, radiation or even 5-FU. A similar effect of IFN on monocyte count has 
also been described for healthy individuals [24]. Even in our data gained from the in vitro mice study, 
the major immunological effects were due to the presence of IFN. Thus, our data and those from others 
reflect the general effects of IFN treatment on leukocytes. 
In the current work, we documented the positive effect of IFN therapy on the DC subpopulation and 
their activation both in human and mice systems. The impaired activity of DC, indicated by reduced 
allostimulatory activity by ex-vivo-generated DC, seems to be common to pancreatic cancer  
patients [27]. Therefore, an increase in the DC activation could be favorable for the patients’  
anti-tumor immunity. In the present work, this effect was significant among all 17 patients after the 
first IFN dose and as we did not observe further significant differences during the course of therapy or 
between the therapeutic groups, we conclude that IFN itself (without subsequent chemotherapy) was 
responsible for this activation. At present, there are no reliable in vivo data from other IFN therapeutic 
trials that demonstrate an IFN impact on DC activation. However, our results were supported by our  
in vitro observations showing the IFN + 5-FU influence on the DC activation status, reflected by 
upregulation of co-stimulatory molecules. These results were supported by observations in vitro, where 
IFN increased alongside the expression of the DC co-stimulatory molecules [28–30].  
T lymphocytes were extensively investigated in this research. We did not observe any effect of IFN 
on CD4+ and CD8+ T cells (including their subpopulations) in vivo both in the human and in the 
murine system. However, direct IFN treatment alone increased the percentage of effector CD8+ cells 
and in combination with 5-FU improved the CD8+/CD4+ ratio. Therefore, we cannot exclude that the 
same positive effects of IFN in vivo might be observed in other experimental settings. 
Following the encouraging data from the Ipilimumab clinical study in malignant melanoma [6], the 
suppression of CTLA4 expression on lymphocytes could be a new strategy in the therapy of some 
immunogenic cancers. In this study, we did not find an influence of IFN or chemo-radio-immunotherapy 
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on CTLA4 expression. Therefore, the immune therapy of pancreatic cancer with monoclonal antibody 
against CTLA4 (i.e., Ipilimumab) could be a new option for ameliorating a combination therapy.  
The augmentation of NK cell activity is important for antitumor response. This has been 
documented in several IFN trials, as well as in other types of immune stimulatory therapies (for review 
see [31]). In our work, we proved an increase of the activated NK cell amount following the first IFN 
injection. This was in line with data from other groups, where increased NK activation was associated 
with stimulatory immunotherapy [32,33]. Additionally, earlier observations showed that the increased 
NK cells mediated cytotoxic activity following IFN treatment [34]. 
In this study, we demonstrated an increased serum level of IFN-γ and IL-10 after IFN therapy. IFN-γ 
acts as a proinflammatory cytokine important to the action of T cells and promotes anti-tumor 
immunity [35]. In opposite to IFN-γ, IL-10 possess anti-inflammatory properties that have an effect on 
keeping a “IFN-γ/IL-10 balance” and can be the indicator of the action of Treg [36]; however, it can 
also potently activate B lymphocytes [37]. Therefore, based on the cytokine serum level, we concluded 
that the unspecific IFN immunotherapy could potentially modulate both pro- and anti-inflammatory 
mediators in patients with pancreatic carcinoma. 
In this clinical trial, the immunosuppressive arm was not accurately assessed. Only Treg were 
traced in this study, but there were no effects on these immunosuppressive cells. These data on Treg 
were confirmed by our in vitro data showing the absence of IFN + 5-FU effects on Treg. Effects of 
IFN on Treg in clinical studies have been investigated in cases of renal RCC [38] and melanoma [39]. 
While in RCC patients, the percentage of Treg decreased immediately after IFN treatment, the amount 
of cells recovered later as treatment processed [38]. In another clinical study with melanoma patients, 
the combination of IFN with tremelimumab (an antibody against CTLA4) induced an increase in Treg 
percentage. The authors assumed that this effect was mainly due to the CTLA4 blockage [39]. 
Therefore, effects of IFN on Treg should be investigated further. 
In regard of MDSC, the orthotopic mouse model of pancreatic cancer was characterized by higher 
accumulation of MDSC in the tumors [40]. Furthermore, the MDSC accumulation was elevated after 
chemo-immunotherapy in both mouse spleens and tumors; this accumulation had a positive correlation 
with tumor growth and simultaneously a negative correlation with the amount of CD4+ cells.  
Our assumption is that this treatment interacts on the MDSC/CD4+ T cell interplay and in turn on 
tumor growth. In vitro effects of combined drug administration was shown only for monocytic  
MDSC. These data point to the importance of immunosuppression (through MDSC) induced by 
combined chemo-immunotherapy. 
Additionally, in this work, we found a high heterogeneity in the initial level of some immunological 
parameters (CTLA4 expression, serum cytokine level, NK-mediated cytotoxicity and antigen specific 
cytotoxicity) prior to IFN therapy in the individual patients. This could potentially have led to the 
different responses to IFN therapy. We suggest initial immunological stratification of patients for 
immunotherapeutical trials. This would allow for precise immunomonitoring and improving the 
response to the therapy. 
Summarizing our human and mouse in vivo and in vitro studies allowed us to conclude that the 
unspecific immunotherapy with interferon type I of patients with pancreatic carcinoma induced not 
only the activation of anti-tumor immunity, but, also, immunosuppressive mechanisms. This might be 
a reason for the absence of clinical benefit for patients treated with the combined therapy in the  
Int. J. Mol. Sci. 2014, 15 4118 
 
 
CapRI-1 study [41,42]. This hypothesis needs more experimental efforts, which should be conducted 
in future immunotherapeutic trials and combined with precise immunomonitoring. 
4. Experimental Section  
4.1. Patients Characteristics and Study Set up 
Patients over the age of 18 years old with biopsy-proven completely resected (R0 or R1 [23]) 
pancreatic adenocarcinoma were eligible for participation in the CapRI-2 study [22]. The final protocol 
was approved by the ethics committee of the University of Heidelberg, Medical School, Heidelberg, 
Germany (AFmu-071/2008). Trial Registration: Current Controlled Trials ISRCTN79802092. Before 
commencing the therapy, patients were informed of the nature and risks of the study by a physician 
and provided their written consent. According to the CapRI-2 protocol [22], patients in study group A 
received a combination of 5-FU, cisplatin and external beam radiation (EBR), including administration 
of IFN (CapRI regimen). The first de-escalation step was group B, where cisplatin had been omitted 
(CapRI-light). The second de-escalation step was group C, where both cisplatin and EBR were left out 
(CapRI ultra-light) (Figure 1). For final data evaluation of the immunological parameters, 17 patients 
were presented. Patients’ characteristics are summarized in Table 1.  
4.2. Time Point of Analysis and Sample Preparation  
Blood samples were taken from the patients immediately prior to the first IFN injection  
pre low-dose IFN (preLDI), one day after (onLDI), immediately before the start of the first cycle of 
chemo-radio-immunotherapy or chemotherapy (pre1), one day after (on1), before the start of the 
second cycle of chemo-radio-immunotherapy or chemotherapy (pre2), and after the third cycle of the 
therapy (end) (Figure 1). Peripheral blood mononuclear cells (PBMC) were isolated from heparinized 
blood samples by Ficoll density gradient centrifugation. The cells were frozen in 10% DMSO (Sigma, 
Deisenhofen, Germany) and 20% fetal calf serum (PAA Laboratories, Cölbe, Germany), and the serum 
samples were stored at −80 °C. EDTA blood was used immediately for flow cytometric analysis. For 
cytotoxicity assays, the monocytes were removed after thawing by adherence to plastic. Leukocyte 
count (all time points except onLDI) was done in the routine analysis center of the Department of 
Clinical Chemistry University Hospital Heidelberg according to the standard operating procedure. 
4.3. Cell Culture 
The murine pancreatic adenocarcinoma cell line Panc02 was originally from Corbett et al. [43]. 
Cells were cultivated in a RPMI-1640 medium with 10% fetal calf serum, 100 U/mL penicillin and  
100 μg/mL streptomycin, (PAA Laboratories, Cölbe, Germany). Cells were cultivated at 37 °C and 5% 
CO2 and routinely checked for mycoplasma contamination. 
4.4. Mice 
C57BL/6 mice (six to eight weeks) were purchased from Charles River (Sulzfeld, Germany) and 
kept under specific pathogen-free conditions in the animal facility of Heidelberg University  
Int. J. Mol. Sci. 2014, 15 4119 
 
 
(IBF, Heidelberg, Germany). Animal experiments were carried out following the approval of the 
German authorities (35-91585.81/G-184/11). 
4.5. Orthotopic Mouse Model of Pancreatic Carcinoma 
Syngeneic pancreatic carcinoma cells were injected orthotopically in C57Bl/6 mice, as described 
elsewhere [40]. Mice were narcotized with isofluran/O2 inhalation. After achieving surgical tolerance 
(stage III2), mice were opened with an abdominal section. A volume of 5 µL of mycoplasma-free 
Panc02 cells in a concentration of 2 × 105 cells/mL PBS were injected into the pancreatic head with a 
25 µL gastight syringe (Hamilton, Reno, NV, USA). The injection site was clamped for about  
30 s after removal of the syringe. The tissue was carefully returned to its original position and all 
layers of the wound (peritoneum, muscles, and skin) were sutured with synthetic absorbable suture 
material (polysorb 6-0, (Tyco Healthcare, Neustadt, Germany)). Mice were treated i.p. with a 
combination of murine recombinant IFN (type I interferon) (1 × 104 units per mouse/day) and 5-FU 
(35 mg/kg/day) on days five, seven, and nine. Tumors and spleens were harvested four weeks after 
Panc02 cell implantations and used for the flow cell biology analysis. 
4.6. Flow Cell Biology Analysis of Human Blood Samples 
Human leukocytes were characterized using following fluorescence labeled anti-human antibodies, 
as described elsewhere [44]: CD45 (for all leukocytes), CD3, CTLA4, FoxP3, CD25, CD56, NKG2D, 
CD69, CD8, CD19, CD45RA, CCR7, CD27, CD33, CD14, CD11c, CD80, CD86, and HLA-DR  
(all BD Biosciences, Heidelberg, Germany). For FACS analyses, antibodies were placed into a 5 mL 
polystyrene round bottom tube and 100 µL blood were added to the tube, which was briefly shaken 
and incubated for 15 min at room temperature. Afterwards, 2 mL 1× BD FACS Lysing Solution (BD 
Biosciences, Germany) was added and further incubated for another 10 min at room temperature, with 
centrifugation following at 200× g for 5 min. The supernatant was removed, the pellet re-suspended in 
2 mL Cellwash solution (BD Biosciences, Heidelberg, Germany) and centrifuged again. Cells were  
re-suspended in 250 µL Cellwash and measured on a BD FACS Canto II flow cytometer (BD 
Bioscience, Heidelberg, Germany). FoxP3 cytoplasmatic staining was performed with a FoxP3-Buffer 
Set and FoxP3-PE antibodies (both from BD Bioscience, Heidelberg, Germany), according to the 
manufacturer’s instructions. Briefly, 400 µL of EDTA-blood was placed into the tube and 1 mL 
Versalyse (Beckman Coulter, Krefeld, Germany) was added; the mix was shaken and incubated for  
10 min, then centrifuged for 5 min with 200× g and re-suspended in 2 mL of Stain buffer  
(BD Biosciences, Heidelberg, Germany). After centrifugation, the supernatant was removed and the 
pellet re-suspended in 100 µL Stain Buffer. Antibodies for cell surface proteins were added for 20 min 
(room temperature); cells were washed twice and fixed with a fixation buffer. For permeabilization, 
cells were supplemented with 0.5 mL of buffer C and incubated for 30 min. After being rinsed twice, 
10 µL of FoxP3-PE antibodies were added and the cells were incubated for 30 min. After being rinsed 
twice again, cells were re-suspended in 250 µL Stain Buffer and measured on a BD FACS Canto II 
flow cytometer (BD Bioscience, Heidelberg, Germany). Data were analyzed with FlowJo software 
(Tree Star, Inc., Ashland, OR, USA).  
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4.7. Flow Cell Biology Analysis of Murine Splenocyte and Tumor Samples 
FACS analysis of murine leukocytes was performed as described elsewhere [40] and will be 
described later in detail. Single cell suspensions of tumors and spleens were prepared in the Stain 
Buffer (PBS supplemented with 1% mouse serum and 1 mM EDTA). The cells were then counted and 
the density adjusted to 4 × 107/mL. The unspecific binding caused by the Fc receptors was blocked by 
incubating the cells with anti-mouse CD16/CD32 antibody (1 μL for 2 × 106 cells) at 4 °C in the dark 
for max 20 min. Then, a 50 μL cell suspension (2 × 106 cells) was incubated with 50 μL of the Stain 
Buffer containing various monoclonal antibodies at 4 °C, also in dark conditions for max 20 min.  
A Foxp3 Staining Buffer set was used for intracellular staining according to the manufacturer’s 
instructions. Acquisition was performed by flow cytometry using FACS Canto II with FACSDiva 
Software (BD Biosciences, Heidelberg, Germany). Specifically, 300,000 events were collected in the 
mononuclear cell gate according to the FSC vs. SSC. Different subsets of Tcon (CD4+FoxP3−) and 
Treg (CD4+CD25+FoxP3+) cells were characterized. Myeloid-derived suppressor cells (MDSC) were 
characterized as CD11b+Gr1+. FlowJo software (Tree Star) was used to analyze at least 500,000 events.  
4.8. In Vitro Treatment of Murine Splenocytes 
Single cell suspensions of spleens were prepared as described elsewhere [45]. Spleens were 
homogenized, squeezed through a 100 and 40 µm cell strainer and flushed with 10 mL of PBS to 
collect as much cells as possible and finally suspended in PBS. The cells were then counted, the 
density adjusted to 2 × 106/mL and 5 mL of this cell suspension was cultivated in a RPMI-1640 
medium with 10% fetal calf serum for 24 h, with or without IFN (5.000 U) + 5-FU (450 μM). After 
that, the cells were gently scratched and proceeded to FACS staining, as mentioned above. 
4.9. Analysis of Human Cytokines with LUMINEX 
Human serum cytokines (interferon γ (IFNγ), tumor-necrosis factor α (TNF-α), IFNγ-induced 
protein 10 (IP10), and interleukin 10 (IL10), IL12 and IL17) were determined using a MILLIPLEX® 
MAP Kit (Millipore GmbH, Schwalbach/TS, Germany) according to the manufacturer’s specifications. 
Briefly, 25 μL of patients’ sera was incubated overnight at 4 °C with color-coded beads coated with 
the capture antibodies for the respective cytokines. After triple rinsing, the beads were incubated with 
the biotinylated secondary detection antibodies for each cytokine/chemokine for one hour at room 
temperature, followed by the final incubation with streptavidin-phycoerythrin for 30 min at room 
temperature. Afterwards, triple rinsing measurements were completed using the Luminex® 100/200 
System (Millipore, Schwalbach/TS, Germany). According to the standard curves, the concentration of 
the respective cytokines was calculated and given as pg/mL. 
4.10. Cytotoxicity Assay 
A standard chromium release assay was used to determine the cytotoxic activity, using  
patients’ PBMC as effector cells and a K562 cell line as a source of target cells. The assay was 
performed as described previously in [44]. 




For the ELIspot for granzyme B, the BD™ ELISPOT Human Granzyme B ELISPOT Set  
(BD Bioscience, San Diego, CA, USA) was used according to the manufacturer’s instructions. 
Patients’ PBMC were stimulated with 100 mg/mL MUC-1 (self-made as described in [44]) or  
100 U/mL CA19.9 (Merck, Schwalbach/TS, Germany), or with the medium as a control. Spots were 
counted after 24 h of incubation using the KSELISPOT System, release 4.1 (Carl Zeiss Light 
Microscopy, Göttingen, Germany). Cells stimulated with the medium without the MUC-1 peptide 
served as controls. 
4.12. Statistical Analysis 
GraphPad Prism Version 5.01 software (Statcon, Witzenhausen, Germany) [46] was used for 
statistical analyses. Distributions of continuous variables were described by means of SE (standard 
error), median, 25% and 75% percentiles and were presented as dot plots. D’Agostino and Pearson 
omnibus normality tests were conducted to estimate the distribution of data. The null hypothesis (mean 
values were equal at all time points of the treatment) versus the alternative hypothesis (mean values 
were not equal) was tested by repeated measures of ANOVA, with Bonferroni’s multiple comparison 
post-hoc test for the normal distributed variants and by Mann-Whitney test for the data that did not 
pass the normality test. Difference in clinical parameters between the study arms was assessed using 
the χ-square test. Correlation analyses of nonparametric data were conducted using the Spearman 
correlation coefficient (r). All statistical tests were two-tailed. The significance level was α = 5%. 
5. Conclusions 
An immunomonitoring of 17 patients with pancreatic cancer from the CapRI-2 study, and  
tumor-bearing mice treated with combination of chemo (radio) therapies with IFN was performed and 
immunological effects of IFN and chemo-radio-immunotherapy with IFN and 5-FU were analyzed in 
this study. The data demonstrated an immunomodulatory response to IFN therapy in pancreatic 
carcinoma patients. Analysis of the Panc02 orthotopic mouse model of pancreatic cancer revealed a 
collateral accumulation of the MDSC in spleens and tumors of the mice treated with IFN and 5-FU, 
which was supported by the direct effect of the drugs on MDSC detected in vitro. Our human and 
mouse in vivo and in vitro studies indicate that the unspecific immunotherapy of pancreatic carcinoma 
with IFN can induce not only the activation of anti-tumor immunity, but also the immunosuppression. 
The data demonstrate the importance of immunosuppressive mechanisms induced by combined 
chemo-immunotherapy and might provide an explanation for the absence of clinical benefit for 
patients in CapRI study. 
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